Clinical Trial Update: Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a combination of imatinib mesylate and 17-N-allylamino-17-demethoxygeldanamycin in patients with chronic myelogenous leukemia; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia

Drugs mentioned

• 17-N-Allylamino-17-Demethoxygeldanamycin (tanespimycin)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Leukemia | Phase 1 | Status: COMPLETED